Sorafenib targets Raf-1 in liver cancer (Wilhelm et al., 2008); Niraparib predominantly binds and inhibits PARP1 and PARP2 in ovarian cancers (From the American Association of Neurological Surgeons et al., 2018); and Enasidenib targets isocitrate dehydrogenase-2 (IDH2) in AML (Del Principe et al., 2019). Here, PARP1 is linked to ovarian carcinoma.